Cannabis and Inflammatory Bowel Disease in Children: What Pediatric Doctors Need to Know
As cannabis legalization spreads, pediatric IBD specialists face growing patient interest in cannabis, but evidence for benefits remains limited while developmental risks for young users are concerning.
Quick Facts
What This Study Found
Writing from Colorado, one of the first states to legalize recreational cannabis, pediatric gastroenterologists described the practical reality of caring for children and adolescents with IBD in an environment of increasing cannabis awareness and acceptance.
The review outlined the endocannabinoid system's role in gastrointestinal function, noting biological plausibility for both beneficial and harmful effects of cannabis in IBD. Cannabis could potentially reduce inflammation and symptoms, but could also impair developing brains and interact with other treatments.
Public perception of cannabis safety had outpaced the evidence, particularly for pediatric populations. The authors noted that federal legal barriers significantly hampered research efforts, making it difficult to generate the evidence needed to guide clinical decisions.
The review emphasized that pediatric gastroenterologists need to understand the cannabis landscape and be prepared to discuss it openly with patients and families, even without definitive evidence.
Key Numbers
Colorado legalized medical cannabis in 2000 and recreational cannabis in 2012. The review does not report specific clinical outcome data.
How They Did This
Narrative review describing the legalization landscape in Colorado, the endocannabinoid system's relevance to IBD, clinical experience with pediatric IBD patients, and research barriers created by federal cannabis scheduling.
Why This Research Matters
This is one of the few reviews addressing cannabis and IBD specifically in pediatric populations. Children and adolescents with IBD face a unique risk-benefit calculus: potential symptom relief versus developmental risks during critical brain maturation periods.
The Bigger Picture
This review captures a transitional moment in cannabis medicine where clinical reality (patients already using cannabis) is ahead of research evidence (insufficient data to guide recommendations). The tension between patient demand and evidence gaps is especially acute in pediatric care.
What This Study Doesn't Tell Us
Primarily a perspective piece from a single institution in Colorado rather than a systematic evidence review. No original clinical data are presented. The pediatric-specific evidence for cannabis in IBD is extremely limited.
Questions This Raises
- ?Could CBD-only preparations offer anti-inflammatory benefits for pediatric IBD without THC-related developmental risks?
- ?Have changes in federal research policies since 2017 improved the ability to study cannabis in children?
- ?What are pediatric IBD patients actually using in legalized states?
Trust & Context
- Key Stat:
- Federal legal barriers significantly hamper research on cannabis for pediatric IBD
- Evidence Grade:
- Narrative clinical perspective from experienced pediatric gastroenterologists. Moderate because it draws on legitimate clinical experience and existing literature but presents no original data.
- Study Age:
- Published in 2017, reflecting the early legal cannabis era in Colorado.
- Original Title:
- Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High.
- Published In:
- Journal of pediatric gastroenterology and nutrition, 64(2), 265-271 (2017)
- Authors:
- Hoffenberg, Edward J(2), Newman, Heike(3), Collins, Colm, Tarbell, Sally, Leinwand, Kristina
- Database ID:
- RTHC-01405
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Should children with IBD use cannabis?
This review does not recommend it. While there is biological plausibility for benefits, the evidence is insufficient to guide treatment in pediatric populations, and developmental risks during brain maturation add additional concern.
Why is it hard to study cannabis for children's diseases?
Federal classification of cannabis as a Schedule I substance creates significant barriers to research, including limited access to standardized products and complex approval processes. This is especially challenging for pediatric research, which requires additional protections.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01405APA
Hoffenberg, Edward J; Newman, Heike; Collins, Colm; Tarbell, Sally; Leinwand, Kristina. (2017). Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High.. Journal of pediatric gastroenterology and nutrition, 64(2), 265-271. https://doi.org/10.1097/MPG.0000000000001393
MLA
Hoffenberg, Edward J, et al. "Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High.." Journal of pediatric gastroenterology and nutrition, 2017. https://doi.org/10.1097/MPG.0000000000001393
RethinkTHC
RethinkTHC Research Database. "Cannabis and Pediatric Inflammatory Bowel Disease: Change Bl..." RTHC-01405. Retrieved from https://rethinkthc.com/research/hoffenberg-2017-cannabis-and-pediatric-inflammatory
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.